Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (15111)	2/14/1998 8:09:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Stan, I foresee heavy duty off-label use of Targretin to treat cancer (including breast), but not as chemoprevention until approval is granted to treat disease such as breast.

To: squetch who wrote (15111)	2/14/1998 8:19:00 PM
From: Henry Niman	Respond to of 32384

LGND's breast cancer results were the top Business Briefing story in Friday's San Diego Union Tribune: BUSINESS BRIEFING SAN DIEGO AND CALIFORNIA Compiled from staff and wire reports 13-Feb-1998 Friday Ligand gains in wake of strong tests Shares of Ligand Pharmaceuticals in San Diego climbed 8 percent after the biotech said results from animal studies of Targretin, its anti-cancer drug, boded well for upcoming human tests. The company said the drug appeared more effective in rats than tamoxifen, the breast-cancer drug that has annual sales of over $500 million. In tests with rats, Ligand's drug caused a tumor regression in 72 percent of the animals that received the drug orally, compared with 33 percent of the animals injected with tamoxifen. Ligand shares closed at $14.50, up $1.12 1/2 .